Eastman Chemical CO Form 4 insider transactions

Christopher M. Killian, SVP & CTO of Eastman Chemical Co., sold 3,061 shares of common stock at $105 per share on November 6, 2024, according to a Form 4 filing.

Director Brett D. Begemann reports acquisition of phantom stock units through deferral of director's fees.

Director Donald W. Slager reports changes in beneficial ownership of Eastman Chemical Co stock due to deferred compensation and dividend reinvestment.

Director James J. O'Brien reports acquisition of phantom stock units through deferral of director's fees.

Director Kim Ann Mink reports acquisition of phantom stock units through Eastman Chemical Co's Directors' Deferred Compensation Plan.

Director Julie Fasone Holder reports acquisition of phantom stock units through deferral of director's fees and dividend equivalents.

Director David W. Raisbeck reports acquisition of phantom stock units through deferral of director's fees.

Director Humberto P. Alfonso increased his holdings in Eastman Chemical Co through the acquisition of phantom stock units via deferral of director's fees.

Director Eric L. Butler reports changes in beneficial ownership of Eastman Chemical Co stock due to deferred compensation and dividend reinvestments.

Director Linnie M. Haynesworth reports acquisition of phantom stock units through deferral of director's fees.

Director Renee J. Hornbaker reports acquisition of phantom stock units through deferral of director's fees and reinvestment of dividend equivalents.

Bosede Ikeolu Gbadegesin, SVP, CLO & Corporate Secretary of Eastman Chemical Co, acquired 16,994 restricted stock units on October 1, 2024, which will vest on October 1, 2027, subject to continued employment.

Adrian James Holt, SVP, Chf HR Ofcr of Eastman Chemical Co., acquired 9,833 restricted stock units on August 1, 2024, which will vest on August 1, 2027.

Director Donald W. Slager reports acquisition of 61 Phantom Stock Units of Eastman Chemical Co through a director's deferred compensation plan.

Adrian James Holt, SVP, Chf HR Ofcr of Eastman Chemical Co, exercised stock options and sold the acquired shares on June 3, 2024.

Eastman Chemical Co.'s EVP & CCO, Brad A. Lich, exercised stock options and sold shares on May 15, 2024.

Director David W. Raisbeck of Eastman Chemical Co. sold 13,500 shares of common stock at a price of $100.5 on May 14, 2024.

Adrian James Holt, SVP, Chf HR Ofcr of Eastman Chemical Co, exercised stock options and sold shares on May 10, 2024.

CEO Mark Costa exercised stock options and sold shares of Eastman Chemical Co on May 7, 2024.

Director Kim Ann Mink acquired 1,252 phantom stock units of Eastman Chemical Co on May 2, 2024, under the Directors' Deferred Compensation Plan.

Director David W. Raisbeck reports acquiring 1,252 shares of Eastman Chemical Co. common stock and disposing of 42,857 shares on May 2, 2024.

Director Eric L. Butler reported acquiring 1,252 shares of Eastman Chemical Co. common stock on May 2, 2024, as part of a restricted stock award.

Director Brett D. Begemann acquired 1,252 phantom stock units of Eastman Chemical Co on May 2, 2024, under the Directors' Deferred Compensation Plan.

Director Humberto P. Alfonso acquired 1,252 phantom stock units under the Directors' Deferred Compensation Plan, deferring a restricted stock award.

Director James J. O'Brien reports acquisition of 1,252 shares of Eastman Chemical Co restricted stock on May 2, 2024, as part of the director's annual Restricted Stock Award.

Director Renee J. Hornbaker reports acquisition of 1,252 shares of Eastman Chemical Co restricted stock on May 2, 2024.

Director Julie Fasone Holder acquired 1,252 shares of Eastman Chemical Co. common stock as a restricted stock award on May 2, 2024.

Director Linnie M. Haynesworth reports acquisition of phantom stock units and deferral of restricted stock award into phantom stock units.

Director Julie Fasone Holder reports acquiring 303 phantom stock units of Eastman Chemical Co through a directors' deferred compensation plan.

Director David W. Raisbeck reports acquisition of phantom stock units through a director's deferred compensation plan.